Format

Send to

Choose Destination
Pharmacogenomics. 2018 Nov 6. doi: 10.2217/pgs-2018-0120. [Epub ahead of print]

Analysis of outpatient HER2 testing in New York state using the statewide planning and research cooperative system.

Author information

1
Harrisburg University of Science & Technology, Harrisburg, PA 17101, USA.
2
Department of Pharmacy Practice, The School of Pharmacy & Pharmaceutical Sciences, The State University of New York at Buffalo, Buffalo, NY 14214, USA.
3
East Coast Institute for Research, Jacksonville, FL 32216, USA.
4
Department of Pharmaceutical Sciences, The School of Pharmacy & Pharmaceutical Sciences, The State University of New York at Buffalo, 470, Kapoor Hall, Buffalo, NY 14214, USA.

Abstract

AIM:

HER2 testing is necessary in the context of therapy with trastuzumab, pertuzumab, lapatinib and neratinib. There is a paucity of reports describing the utilization rates of HER2 testing in large outpatient populations.

METHODS:

The Statewide Planning and Research Cooperative System (SPARCS) was used to examine HER2 testing across the state of New York (USA) during the 2012-2016 period.

RESULTS:

There was a linear increase in HER2 testing (r = 0.91, p = 0.030). There were increases in HER2 testing observed among minorities, including 0.5-fold and 3.5-fold increases in individuals identified as black and Asian, respectively. Major state population centers showed the highest HER2 testing.

CONCLUSION:

This study establishes a platform to further evaluate clinical utility, outcomes and equity of access for 'precision oncology' testing.

KEYWORDS:

CPT code; HER2; HercepTest; New York state; SPARCS database; breast cancer; lapatinib; pharmacogenomics; trastuzumab

PMID:
30398082
DOI:
10.2217/pgs-2018-0120

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center